Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) EBIT per Share : $-0.05 (TTM As of Apr. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics EBIT per Share?

Advanced Proteome Therapeutics's EBIT per Share for the three months ended in Apr. 2023 was $-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2023 was $-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Advanced Proteome Therapeutics's EBIT per Share or its related term are showing as below:

APTCF's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Advanced Proteome Therapeutics's EBIT for the three months ended in Apr. 2023 was $-1.50 Mil.

Advanced Proteome Therapeutics EBIT per Share Historical Data

The historical data trend for Advanced Proteome Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics EBIT per Share Chart

Advanced Proteome Therapeutics Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

EBIT per Share

Get a 7-Day Free Trial

-0.06

-0.03

-0.02

-0.06

0.02

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
EBIT per Share	Get a 7-Day Free Trial															-0.01	-	-0.01	-0.01	-0.04

Advanced Proteome Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Advanced Proteome Therapeutics's EBIT per Share for the fiscal year that ended in Jul. 2022 is calculated as

	EBIT per Share		(A: Jul. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.627	/	39.088
=	0.02

Advanced Proteome Therapeutics's EBIT per Share for the quarter that ended in Apr. 2023 is calculated as

	EBIT per Share		(Q: Apr. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.498	/	40.711
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05

Advanced Proteome Therapeutics (OTCPK:APTCF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Advanced Proteome Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0E81:Germany APC.H:Canada

Address

8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2

Website

https://www.advancedproteome.com

Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines

From GuruFocus

Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement

By GlobeNewswire GlobeNewswire • 08-23-2018

Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as Chief Executive Officer, President and Director

By GlobeNewswire GlobeNewswire • 06-06-2018